Improper peri-implantation placental development may contribute to feto-maternal diseases (preterm birth, intrauterine growth retardation, preeclampsia) and high rates of pregnancy loss. Since these events occur prior to clinical detection of pregnancy, studies of very early human placental development are ethically and logistically constrained. The proposed project uses an innovative human embryonic stem cell (hESC)-derived model to study primitive trophoblast in vitro. The placenta resembles a cancer in that an implanting fetus and a developing cancer both involve host tissue invasion, massive cellular proliferation, neo-vascularization, and alterations in the immediate immune microenvironment. The placenta of the implanting fetus is one of the only non-cancerous tissues that displays physiologic downregulation of the classical major histocompatibility complex (MHC) class I (MHC-I) transplantation antigens, human leukocyte antigens (HLA)-A and -B. While positive regulatory elements for MHC class II regulation are described, little is known about such regulation of MHC class I expression in noncancerous tissues, including the placenta. Human embryonic stem cells (hESCs) have been used in a novel in vitro model of the stages of human placental development that occur prior to clinical detection of pregnancy. Several mRNAs and proteins that are selectively expressed at high levels in early pregnancy have been identified by using the model. Of those studied, all appear to play roles in invasion. Remarkably, siRNA silencing of one of these proteins, V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1), in our model for early trophoblast strongly up-regulated the expression of the MHC class I human leukocyte antigens (HLA)-A and -B, which are normally not expressed in human trophoblast, slightly up-regulated the normally resident HLA-C, but had no effect on expression of the placenta-specific HLA-G. VTCN1 is recognized as a member of the B7 superfamily of cell-surface co-receptors that regulate T cell receptor interactions with MHC molecules. It has been postulated that VTCN1 neo-expression affects cancer cells’ ability to evade host immune detection. These results highlight the efficacy of our in vitro models for filling several important knowledge gaps. The unique ability to model peri-implantation placental development in vitro will enable dissection of the control of MHC-I expression on human trophoblast (TB), particularly testing the hypothesis that the lack of expression of HLA-A and -B by TB is controlled by VTCN1 through largely indirect mechanisms. There are three aims to the proposal: 1) Demonstrate classical MHC class I suppression by VTCN1 in various TB models, including hESC-derived primitive trophoblast, by using VTCN1 knock-down and overexpression; 2) Define the transcriptional pathways and transcriptional and immediate post-transcriptional regulation involved in VTCN1-related alterations in TB MHC-I expression and 3) Identify ...